Title:
VINYL-SUBSTITUTED PYRIDINE COMPOUNDS
Document Type and Number:
WIPO Patent Application WO/2021/180006
Kind Code:
A1
Abstract:
Provided are a class of vinyl-substituted pyridine compounds (I) and pharmaceutically acceptable salts thereof, and the use of the compounds and the pharmaceutically acceptable salts thereof in the preparation of drugs for treating related diseases.
Inventors:
LU JIANYU (CN)
HE HUIJUN (CN)
HU GUOPING (CN)
HU LIHONG (CN)
DING CHARLES Z (CN)
LI JIAN (CN)
CHEN SHUHUI (CN)
HE HUIJUN (CN)
HU GUOPING (CN)
HU LIHONG (CN)
DING CHARLES Z (CN)
LI JIAN (CN)
CHEN SHUHUI (CN)
Application Number:
PCT/CN2021/079337
Publication Date:
September 16, 2021
Filing Date:
March 05, 2021
Export Citation:
Assignee:
MEDSHINE DISCOVERY INC (CN)
International Classes:
C07D401/12; A61K31/395; A61K31/496; A61K31/505; A61P35/00; C07D239/46; C07D403/02
Domestic Patent References:
| WO2019148036A1 | 2019-08-01 |
Foreign References:
| CN107793363A | 2018-03-13 | |||
| CN110862397A | 2020-03-06 | |||
| CN102256493A | 2011-11-23 | |||
| CN102964308A | 2013-03-13 | |||
| CN108530464A | 2018-09-14 |
Other References:
CHIA STEPHEN K., ELLARD SUSAN L., MATES MIHAELA, WELCH STEPHEN, MIHALCIOIU CATALIN, MILLER WILSON H., GELMON KAREN, LOHRISCH CAROL: "A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer", BREAST CANCER RESEARCH, CURRENT MEDICINE GROUP LTD., GB, vol. 19, no. 1, 54, 1 December 2017 (2017-12-01), GB, pages 1 - 8, XP055846788, ISSN: 1465-5411, DOI: 10.1186/s13058-017-0836-3
Attorney, Agent or Firm:
BEIJING ORIGINTELLIGENCE IP LAW FIRM (CN)
Download PDF:
Previous Patent: INFORMATION PROCESSING METHOD AND ELECTRONIC DEVICE
Next Patent: SERVICE BEARING METHOD, APPARATUS AND SYSTEM
Next Patent: SERVICE BEARING METHOD, APPARATUS AND SYSTEM